Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer

BJU International

Volumn 111, Issue 8, 2013, Pages

  Meeks, Joshua J ^a   Taylor, Jennifer M ^a   Matsushita, Kazuhito ^a   Herr, Harry W ^a   Donat, S Machele ^a   Bochner, Bernard H ^a   Dalbagni, Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

bladder cancer; chemotherapy; lymph node metastasis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; SUNITINIB; VINBLASTINE;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CYSTECTOMY; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; MUSCLE INVASIVE MICROPAPILLARY BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEW YORK; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84878297972     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11751.x     Document Type: Article

References (13)

1. Soloway MS,. Cis-diamminedichloroplatinum II in advanced urothelial cancer. J Urol 1978; 120: 716-719 (Pubitemid 9091405)
2. Merrin C,. Treatment of advanced bladder cancer with cis- diamminedichloroplatinum (II NSC 119875): a pilot study. J Urol 1978; 119: 493-495 (Pubitemid 8341473)
3. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354: 533-540
4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866 (Pubitemid 37025405)
5. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-1018
6. Kamat AM, Gee JR, Dinney CPN, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006; 175: 881-885 (Pubitemid 43200002)
7. Kamat AM, Dinney CPN, Gee JR, et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007; 110: 62-67 (Pubitemid 46986419)
8. Amin MB, Ro JY, el-Sharkawy T, et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994; 18: 1224-1232 (Pubitemid 24362435)
9. Black PC, Brown GA, Dinney CPN,. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009; 27: 3-7
10. Johansson SL, Borghede G, Holmäng S,. Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 1999; 161: 1798-1802 (Pubitemid 29420734)
11. Rosenblatt R, Sherif A, Rintala E, et al. Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer. Eur Urol 2011; 61: 1229-1238
12. Scosyrev E, Ely BW, Messing EM, et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 2011; 108: 693-699
13. Sangoi AR, Beck AH, Amin MB, et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 2010; 34: 1367-1376